Western Equine Encephalitis – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Western Equine Encephalitis – Pipeline Review, H2 2016’, provides an overview of the Western Equine Encephalitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Western Equine Encephalitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Western Equine Encephalitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Western Equine Encephalitis

The report reviews pipeline therapeutics for Western Equine Encephalitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Western Equine Encephalitis therapeutics and enlists all their major and minor projects

The report assesses Western Equine Encephalitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Western Equine Encephalitis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Western Equine Encephalitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Western Equine Encephalitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Akshaya Bio Inc

Altravax Inc

EpiVax Inc

H&P Labs Inc

Profectus BioSciences Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Western Equine Encephalitis Overview 6

Therapeutics Development 7

Pipeline Products for Western Equine Encephalitis - Overview 7

Pipeline Products for Western Equine Encephalitis - Comparative Analysis 8

Western Equine Encephalitis - Therapeutics under Development by Companies 9

Western Equine Encephalitis - Therapeutics under Investigation by Universities/Institutes 10

Western Equine Encephalitis - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Western Equine Encephalitis - Products under Development by Companies 13

Western Equine Encephalitis - Products under Investigation by Universities/Institutes 14

Western Equine Encephalitis - Companies Involved in Therapeutics Development 15

Akshaya Bio Inc 15

Altravax Inc 16

EpiVax Inc 17

H&P Labs Inc 18

Profectus BioSciences Inc 19

Western Equine Encephalitis - Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Drug Profiles 29

DEF-201 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

equine encephalitis (trivalent) vaccine - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

equine encephalitis vaccine - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

equine encephalitis vaccine - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Vaccine for Western Equine Encephalitis - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Westrern Equine Encephalitis Virus Vaccine - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Western Equine Encephalitis - Dormant Projects 36

Western Equine Encephalitis - Product Development Milestones 37

Featured News & Press Releases 37

Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses 37

Appendix 38

Methodology 38

Coverage 38

Secondary Research 38

Primary Research 38

Expert Panel Validation 38

Contact Us 38

Disclaimer 39

List of Tables

List of Tables

Number of Products under Development for Western Equine Encephalitis, H2 2016 7

Number of Products under Development for Western Equine Encephalitis – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Western Equine Encephalitis – Pipeline by Akshaya Bio Inc, H2 2016 15

Western Equine Encephalitis – Pipeline by Altravax Inc, H2 2016 16

Western Equine Encephalitis – Pipeline by EpiVax Inc, H2 2016 17

Western Equine Encephalitis – Pipeline by H&P Labs Inc, H2 2016 18

Western Equine Encephalitis – Pipeline by Profectus BioSciences Inc, H2 2016 19

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Stage and Target, H2 2016 22

Number of Products by Stage and Mechanism of Action, H2 2016 24

Number of Products by Stage and Route of Administration, H2 2016 26

Number of Products by Stage and Molecule Type, H2 2016 28

Western Equine Encephalitis – Dormant Projects, H2 2016 36

List of Figures

List of Figures

Number of Products under Development for Western Equine Encephalitis, H2 2016 7

Number of Products under Development for Western Equine Encephalitis – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Top 10 Targets, H2 2016 21

Number of Products by Stage and Top 10 Targets, H2 2016 21

Number of Products by Mechanism of Actions, H2 2016 23

Number of Products by Stage and Mechanism of Actions, H2 2016 23

Number of Products by Routes of Administration, H2 2016 25

Number of Products by Stage and Routes of Administration, H2 2016 25

Number of Products by Molecule Types, H2 2016 27

Number of Products by Stage and Molecule Types, H2 2016 27

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports